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SSRI (selective serotonin reuptake inhibitor)Cognitive decline occurs during healthy aging, even in middle-aged subjects, viamechanisms that could include
reduced stem cell proliferation, changed growth factor expression and/or reduced expression of synaptic plastic-
ity genes. Although antidepressants alter these mechanisms in young rodents, their effects in older animals are
unclear. In middle-aged mice, we examined the effects of a selective serotonin reuptake inhibitor (ﬂuoxetine)
and a multimodal antidepressant (vortioxetine) on cognitive and affective behaviors, brain stem cell prolifera-
tion, growth factor and gene expression. Twelve-month-old female C57BL/6 mice exhibited impaired visuospa-
tial memory in the novel object placement (location) task associated with reduced expression of several
plasticity-related genes. Chronic treatment with vortioxetine, but not ﬂuoxetine, improved visuospatial memory
and reduced depression-like behavior in the forced swim test in middle-aged mice. Vortioxetine, but not ﬂuox-
etine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g.,
Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Neither drug reversed the age-associated decrease
in stem cell proliferation. Hippocampal growth factor levels were not consistent with behavioral outcomes.
Thus, a change in the expression of multiple genes involved in neuronal plasticity by antidepressant treatment
was associated with improved cognitive function and a reduction in depression-like behavior in middle-aged
mice.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although severe cognitive deﬁcits notably occur in dementia and
neurodegenerative diseases, mild cognitive deﬁcits are also prevalent
in otherwise healthy older subjects in both humans and in rodent
models (Aenlle et al., 2009; Dumas et al., 2013; Ennaceur et al., 2008;
Gautam et al., 2011; Gunstad et al., 2006; Salthouse, 2010). Thus, in
the following we focus on the physiology of age-related cognitive
changes in otherwise healthy middle-aged subjects as such studies; ANOVA, analysis of variance;
romo-2′-deoxyuridine; ELISA,
-1, insulin-like growth factor 1;
merase chain reaction; SSRI, se-
porter; TBS, tris-buffered saline;
R, vortioxetine.
artment ofNeuroscience, Albert
Kennedy Center, RM 925, 1410
ulinello).
. This is an open access article undermay elucidate early changes in mechanisms of age-related cognitive
deﬁcits.
Several mechanisms have been proposed to explain age-related
decline in cognitive performance, including decreased neurogenesis, re-
duced growth factor levels and synaptic plasticity, and morphological
changes. Decreased neurogenesis in old and middle-aged subjects
(Ben Abdallah et al., 2010; Kuhn et al., 1996; Spalding et al., 2013) is pri-
marily due to decreased precursor cell (stem cell) proliferation (Olariu
et al., 2007) and may be associated with deﬁcits in hippocampal-
mediated tasks (Clelland et al., 2009). Age-related changes in the levels
of neurotrophic factors have also been shown in middle-aged rodents
(Bimonte-Nelson et al., 2008; Hattiangady et al., 2005; Shetty et al.,
2005). Decreased plasticity in middle-aged and aged rodents (Kumar,
2011; Rex et al., 2005) may also play a role in cognitive impairment
(Balietti et al., 2012). In this context, it is interesting that antidepres-
sants, which have been shown to have pro-cognitive effects in some an-
imal models (Elizalde et al., 2008; Schilstrom et al., 2011), also alter
stem cell proliferation (Ibi et al., 2008), growth factor expression
(Song et al., 2006) and neuroplasticity-related gene expression
(Djordjevic et al., 2012; Freitas et al., 2013), which could underlie thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of particular importance as even sub-threshold depressive symptoms
negatively impact cognitive functions in middle-aged and old subjects
(Brevik et al., 2013).
Both selective serotonin reuptake inhibitors (SSRIs) and vortioxetine
(1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine) are antide-
pressants that may improve cognitive function (Biringer et al., 2009;
Egashira et al., 2006; ElBeltagy et al., 2010; Mork et al., 2013; Wallace
et al., 2014) and increase stem cell proliferation in young adult rodents
(Guilloux et al., 2013; Ohira et al., 2013), but their effects in older ani-
mals have not been well studied. In addition, SSRIs and vortioxetine
have different mechanisms of action. Vortioxetine is a multimodal anti-
depressant that inhibits the serotonin transporter (SERT), and is also an
antagonist for 5-HT1D, 5-HT3, and 5-HT7 receptors, a partial agonist for
5-HT1B receptors and an agonist for 5-HT1A receptors (Bang-Andersen
et al., 2011). In clinical studies, vortioxetine improves cognitive perfor-
mance in adults (McIntyre et al., 2014) as well as elderly patients with
depression (Katona et al., 2012), even though this population tends to
be less responsive to the effects of SSRIs (Tedeschini et al., 2011).
Thus, it is of interest to examine the effects of both agents in middle-
aged mice.
In the current study, we ﬁrst characterized deﬁcits in a battery of
behavioral tests in healthy middle-aged (12 month) and young
(3month)mice.We then assessed the behavioral effects of vortioxetine
and ﬂuoxetine in the middle-aged mice. To elucidate the underlying
mechanisms of the observed differences, we also examined age- and
drug-induced effects on hippocampal cell proliferation, growth factor
levels and expression of plasticity-related genes in relevant brain
regions.
2. Materials and methods
2.1. Animals
Female C57BL/6 mice of different ages (40 young — 3 months and
120 middle-aged — 11 months) were acquired from Charles River
(Wilmington, MA), and group housed (2 per cage). Animals were kept
under a 12:12 light:dark cycle (lights on 6 am, lights off 6 pm) with ad
libitum access to water and food. All animal experiments were conduct-
ed in accordance to the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the U.S. National Institutes of
Health, and approved by the Institutional Animal Care and Use Commit-
tee of Lundbeck Research USA.
2.2. Experimental design
Eleven-month-old mice were randomly divided into three groups
(40 mice per treatment group) and received 1 month of vortioxetine,
ﬂuoxetine or vehicle treatment. The vortioxetine group mice were fed
with Purina 5001 rodent chow containing vortioxetine (synthesized
by H. Lundbeck A/S, Valby, Denmark) at a concentration of 600 mg
base per kg food (Research Diets Inc., New Brunswick, NJ) and drank
plain tap water. The ﬂuoxetine group mice were fed with Purina 5001
rodent chow and drank ﬂuoxetine in tap water (synthesized by H.
Lundbeck A/S, Valby, Denmark) at a concentration of 143 mg base per
liter. The vehicle group was fed with Purina 5001 rodent chow and
drank plain tap water. Drug concentrations of both ﬂuoxetine and
vortioxetine were chosen to reach therapeutic dose range based on
brain SERT occupancy results from previous studies (Li et al., 2013)
and conﬁrmed with ex vivo radio-autography analysis. Body weights
were also monitored to conﬁrm no gross changes in animal's feeding
behavior. At 12 months of age, 20 mice of each treatment group
underwent behavioral tests. Four behaviorally tested 12 month old
mice from each drug treated group were used in ex vivo radio-
autography measurement of SERT occupancy, to conﬁrm sufﬁcient
drug exposure. Remaining behavioral test-naive animals were used forBrdU uptake assay, qPCR and various growth factor quantiﬁcations.
Similar numbers of young mice (3 months old) were included as
controls. Detailed sample sizes are described in the Results section and
ﬁgure legends.
2.3. Behavioral tests
Behavioral tests were conducted in the following order: open ﬁeld,
novel object placement, novel object recognition, social preference
and forced swim test. Animals received one test per day, with at least
one day between tests. Animals were brought into the laboratory for
acclimatization at least 30 min prior to behavioral testing. All tests
were conducted under low levels of incandescent lighting between
9 am and 5 pm.
2.3.1. Open ﬁeld test (OF)
Animals were allowed to freely explore a testing arena (50 cm ×
50 cm× 35 cm) for 6min and their activity was analyzed using track-
ing software (Viewer, Biobserve, Bonn, Germany). General locomo-
tor activity was assessed as total track length and anxiety-like
behavior as the proportion of activity occurring in the center of the
arena (% center activity = 100 × center track length / total track
length).
2.3.2. Novel object placement (OP)
Visuospatial memory was examined using a novel object placement
test (a.k.a. novel object location test, place recognition test, or spatial
novelty test) (Ennaceur and Meliani, 1992; Yassine et al., 2013). Brieﬂy,
micewere ﬁrst allowed to explore in an open ﬁeld containing two iden-
tical objects (with high contrast intra-arena visual cues) for 3min (Trial
1— training trial). The amount of object exploration (deﬁned as rearing
on, whisking, snifﬁng or touching the objects with nose and/or
forepaws) was scored manually using stopwatches. After a retention
interval of 45min, micewere returned to the same testing arena for an-
other 3min (Trial 2— testing trial), with one objectmoved to a different
location. Exploration of each object was again manually scored. Results
of the object placement test were reported as novel object placement
preference scores (100% × exploration during testing trialrelocated object /
total object exploration during testing trial). Animals with intact visuo-
spatial memory preferentially explore the relocated (novel) object and
thus would have a preference score N50%. The results of the object
placement test were also reported as the proportion of animals failing
and passing, with passing deﬁned as preference score N55%. Criteria
for establishing a pass/fail cutoff are detailed and justiﬁed elsewhere
(Li et al., 2010). Brieﬂy, several factors were taken into consideration:
individual variability when animals repeat a task, within- and
between-cohort performance stability andmeasurement error. In addi-
tion, typically very few subjects have preference scores between 53%
and 55% and thus changing the criteria within this range does not sub-
stantively alter the results. Total novel object exploration (s) during
Trial 1 is also illustrated as an internal control. Track length was mea-
sured by Viewer tracking software (Biobserve, Bonn, Germany).
2.3.3. Novel object recognition (OR)
Recognition memory was assessed using the novel object recogni-
tion test (Dere et al., 2007; Ennaceur and Delacour, 1988). Brieﬂy,
mice were allowed to explore two identical objects in the testing
arena for 3 min (Trial 1 — training trial). After a retention interval of
2 h, mice were returned to the arena for another 3 min, with one of
the familiar objects now replaced by a novel object (Trial 2 — testing
trial). The amount of exploration was scored manually. As in the object
placement test, the performance was evaluated by preference score
(100% × exploration during testing trialnovel object / total testing trial
object exploration) as well as pass/fail (using preference score N55%
as the criterion).
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Social withdrawal was measured in a social preference test
(Crawley, 2004). Brieﬂy, mice were allowed to explore a 3-chambered
testing arena containing either a stimulus conspeciﬁc animal (ovariec-
tomized female) in a wire mesh cage or a similar sized inanimate object
in an identical cage for 10 min. The amount of time each animal spent
exploring (deﬁned as rearing on, whisking, snifﬁng or touching the
mesh enclosure with nose and/or forepaws) the stimulus animal or
the object was scored manually and is expressed as a social preference
score (100% × explorationstimulus animal / total exploration).
2.3.5. Forced swim test (FS)
Depression-like behavior was assessed by a modiﬁed forced swim
test (Porsolt et al., 1977). Brieﬂy, mice were put in plexiglass cylinders
(20 cm in diameter) ﬁlledwith 25 °Cwater (30 cm deep) for 4min. Im-
mobility was manually scored using stopwatches, excluding the ﬁrst
minute of the trial. Immobility was deﬁned as no movement other
than that necessary to keep the animal's head above water. Results
are presented as % immobility: 100% × immobile period (s)/180. The
immobility in the forced swim test has been extensively validated as a
measure of depression-like behavior. Firstly, it is sensitive to and pre-
dictive of the success of antidepressants (Cooper et al., 1980; Dulawa
et al., 2004; Harkin et al., 1999; Karpa et al., 2002; Kusmider et al.,
2006; Porsolt et al., 1978;Willner, 1995). Secondly,many of the circum-
stances thought to promote depression in humans also induce behav-
ioral ‘despair’ in the forced swim test (Boccia et al., 2007; Bulduk and
Canbeyli, 2004; Friedman et al., 2006; Hoshaw et al., 2006; Hwang
et al., 1999; Lee et al., 2007; Pare, 1992; Ruedi-Bettschen et al., 2006;
Wann et al., 2007; Willner, 1995; Willner and Mitchell, 2002). Lastly,Table 1
Hippocampal gene expression levels were reduced inmiddle-agedmice.Hippocampal gene
↓: signiﬁcant reduction.
Gene Protein Function
Transcription and translation factors
Nfkb1a Nuclear factor NF-κB p105 subunit Part of NF-κB tr
Fosa (c-Fos) FBJ murine osteosarcoma viral oncogene homolog Part of transcrip
Fmr1a Fragile X mental retardation protein Transport mRN
Creb1 cAMP responsive element binding protein 1 Phosphorylation
Signal transduction
Ntrk2 (TrkB) Neurotrophic tyrosine receptor kinase Receptor for ne
neurotrophin-3
Camk2aa Calcium/calmodulin-dependent protein kinase II α Serine/threonin
long-term poten
Prkca Protein kinase C-α Serine/threonin
pathway
Jak2 Janus kinase 2 Tyrosine kinase
Gsk3b Glycogen synthase kinase 3β Serine/threonin
pathway
Synaptic plasticity
Arca Activity-regulated cytoskeleton-associated
protein
Required for syn
Shank1a SH3 and multiple ankyrin repeat domains 1 Adapter protein
synapses
Nlgn2a Neuroligin 2 Cell adhesion m
Homer1 Homer protein homolog 1 Postsynaptic de
Ncam1 Neural cell adhesion molecule 1 Cell adhesion m
Dlg4 (Psd-95) Postsynaptic density protein 95 Postsynaptic de
Neurotransmission
Syp Synaptophysin Small synaptic v
Scg3 Secretogranin-3 Protein located
Snap25 Synaptosomal-associated protein 25 Docking of synap
membrane
Vamp1 Vesicle-associated membrane protein 1,
Synaptobrevin 1
Docking of synap
membrane
Htr1d Serotonin receptor 1D G-protein (Gi/G
Grin1 (Nmdar1) Glutamate Receptor Ionotropic, NMDA 1 Ligand-gated ca
a Indicates gene expression levels also changed by antidepressant treatment. For the full listthe physiological responses, the brain regions and underlying mecha-
nisms regulating immobility in the forced swim test behavior are simi-
lar to ﬁndings in depressed humans (Arletti and Bertolini, 1987; Flugy
et al., 1992; Gil et al., 1992; Hattori et al., 2007; Hwang et al., 1999;
Jesberger and Richardson, 1985; Kostowski, 1985; Kostowski et al.,
1984; McKinney, 1984; Overstreet, 1986; Pare, 1989, 1992; Porsolt,
1979; Porsolt et al., 1979; White et al., 2007; Willner, 1984, 1995) and
to other animal assays of depression (Gil et al., 1992; Kostowski et al.,
1992; Pare, 1994; Willner, 1995).
2.4. Quantitative PCR (qPCR)
Dissected hippocampal tissues were stored in Ambion RNAlater®
reagent (Life Technologies, Grand Island, NY) at−20 °C until analysis.
RNA was isolated from hippocampal homogenates using an Ambion
RNAqueous kit (Life Technologies) and mRNA was enriched by remov-
ing genomic DNA with a DNase digestion step. RNA concentration and
quality was determined using an Agilent Bioanalyzer (Agilent Technol-
ogies, Santa Clara, CA). Reverse transcription of mRNA to cDNA was ac-
complished using Superscript II™ (Life Technologies). Reactions were
performed in duplicate using 600 ng of RNA. The cDNA from the two re-
actions was pooled and quantiﬁed using a dye intercalation assay
(Quant-iT™ OliGreen® ssDNA Assay Kit, Life Technologies), according
to the manufacturer's instructions. For qPCR assays, 384-well plates
containing 2, 10 or 20 ng of each cDNA per well were used to allow
the characterization of low, medium or highly expressed transcripts.
All qPCR assays (10 μl) were performed in duplicate using an Applied
Biosystems 7900HT Fast Real Time PCR System (Life Technologies).
Primers and probes were designed using Primer Express® software (Lifeexpression levels were measured by qPCR and normalized using 3 month old mice as 100.
Middle-aged
vs. young
Young Middle-aged
anscription factor ↓ 100 ± 7 83 ± 3
tion factor complex Jun/AP-1 ↓ 100 ± 15 44 ± 6
A ↓ 100 ± 5 88 ± 4
-dependent transcription factor ↓ 100 ± 3 86 ± 3
urotrophic factors (BDNF,
and neurotrophin-4)
↓ 100 ± 5 83 ± 3
e kinase required for hippocampal
tiation (LTP) and spatial learning
↓ 100 ± 7 83 ± 3
e kinase in signal transduction ↓ 100 ± 5 85 ± 3
in signal transduction pathway ↓ 100 ± 3 84 ± 4
e kinase in signal transduction ↓ 100 ± 4 88 ± 3
aptic plasticity and memory formation ↓ 100 ± 12 68 ± 5
in the postsynaptic density of excitatory ↓ 100 ± 8 80 ± 2
olecule, binding partner of neurexins ↓ 100 ± 6 80 ± 4
nsity scaffolding protein ↓ 100 ± 3 84 ± 3
olecule ↓ 100 ± 4 88 ± 4
nsity scaffolding protein ↓ 100 ± 7 85 ± 3
esicles membrane protein ↓ 100 ± 4 81 ± 3
in secretory vesicles ↓ 100 ± 4 87 ± 3
tic vesicles with the presynaptic plasma ↓ 100 ± 4 88 ± 3
tic vesicles with the presynaptic plasma ↓ 100 ± 4 88 ± 3
o) coupled serotonin receptor ↓ 100 ± 11 71 ± 6
tion channel ↓ 100 ± 4 85 ± 3
of genes please see Table S1.
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orwere purchased premade fromApplied Biosystems (Life Technologies).
Enzyme for qPCR reaction (SensiFAST™ Hi-Rox) was purchased from
Bioline (Taunton, MA) and used according to the manufacturer's in-
structions. Normalization of raw qPCR signals was performed using
the geometric mean of a panel of 7 house-keeping genes (B2m, Ppia,
Gapdh, Rplp0, Rpl13a, Tbp, Ubc) that were selected for their stable ex-
pression based on the geNorm algorithm (Vandesompele et al., 2002).
No signiﬁcant change in the expression levels of housekeeping genes
was found between all groups. The relative expression level of each
targetwas calculated using the comparative threshold cycle (Ct)method,
with the expression level of vehicle-treated young mice (when analyze
age associated changes, Table 1) or vehicle-treated middle-aged mice
(when analyze treatment associated changes, Fig. 4 and Table S1) de-
ﬁned as 100.
2.5. BrdU uptake assay
Hippocampal cell proliferation was assessed by quantifying the
number of cells in the sub-granular zone of the dentate gyrus labeled
by 5-bromo-2′-deoxyuridine (BrdU), based on published protocols
(Wojtowicz and Kee, 2006). Brieﬂy, mice were intraperitoneally
injected 4 timeswith 50mg/kg BrdU (Sigma, St. Louis,MO)with 2 h be-
tween injections and sacriﬁced the next day. Brains were ﬁxed by trans-
cardiac perfusion with phosphate-buffered saline followed by 4%
paraformaldehyde (Affymetrix, Santa Clara, CA) and post ﬁxed in 4%
paraformaldehyde overnight. After equilibrating in 30% sucrose, brains
were stored in−80 °C and later cryosectioned into 30 μm slices using
a microtome (Thermo Scientiﬁc, Waltham, MA). Free-ﬂoating hippo-
campal slices underwent antigen retrieval (2 M HCl at 37 °C for
30 min followed by rinsing in 0.1 M borate buffer), membrane perme-
ation (0.5% Triton X-100 in tris-buffered saline (TBS) at room tempera-
ture for 45 min), quenching of endogenous peroxidase activity (0.3%
H2O2 at room temperature for 10min), blocking of non-speciﬁc binding
(5% goat serum (Vector Laboratories, Burlington, CA) in TBS at room
temperature for 45 min), primary antibody labeling (1:1000 anti-BrdU
antibody developed in rat (Accurate Chemical & Scientiﬁc Corporation,
Westbury, NY) in 5% goat serum/TBS 4 °C overnight), secondary anti-
body reaction (1:200 goat anti-rat IgG, mouse adsorbed (Victor Labora-
tories, Burlingame, CA)) and visualized using an avidin–biotin complex
labeled peroxidase system (Vectastain Elite ABC kit, Vector Laborato-
ries) with 3,3′-diaminobenzidine (DAB) as the chromogen. Extensive
wash (5 min × 5 times) were carried out between each incubation
steps. Brain slices were then transferred to gelatin coated slides (Fisher
Scientiﬁc, Waltham, MA), dehydrated by dipping in increasing concen-
trations of ethanol (50%, 70%, 95% and 100%) and washed in xylene.
Coverslips were placed on slides in the presence of DPX mounting
media (Electron Microscopy Sciences, Hatﬁeld, PA). BrdU-positive cells
were manually counted under a microscope (Zeiss, Oberkochen,
Germany, total magniﬁcation: 100×) for every 6th hippocampal slices,
throughout the rostrocaudal extent of the dentate gyrus in the
subgranular zone (within a two-nucleus thick region from the granular
cell layer), essentially as previously described (Walter et al., 2011). The
total number of BrdU-positive cells from 10 sub-granular regions is
reported.
2.6. Protein extraction and enzyme-linked immunosorbent assay (ELISA)
Dissectedhippocampiwere snap frozen and stored in−80 °C. Tissue
washomogenized using pellet pestles (Sigma) followed by sonication in
lysis buffer (25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and
1mMEGTA) containing protease inhibitors (cOmplete® protease inhib-
itor cocktail, Roche, Mannheim, Germany) on ice and constant agitation
at 4 °C for 1 h. After centrifugation (30 min at 13,000 rpm and 4 °C),
protein concentration of the supernatant was measured using a
Micro BCA kit (Thermo Scientiﬁc, Waltham, MA). Growth factor(BDNF, NT-3, IGF-1, NGF, and VEGF) levels were quantiﬁed using
ELISA kits, following the instructions of the manufacturer (Genway
Biotech, San Diego, CA). Results were standardized to the protein
concentration of each lysate sample.
2.7. Ex vivo autoradiography to determine serotonin transporter (SERT)
occupancy
To ensure that middle-aged mice in different treatment groups
received antidepressants in therapeutic ranges, SERT occupancy was
measured in ex vivo autoradiography experiments; detailed methods
have been described elsewhere (Li et al., 2012).
2.8. Statistical analysis
JMP10 (SAS, Cary, NC)was used for all statistical analysis. For behav-
ioral tests, quantiﬁcation of hippocampal cell proliferation and growth
factor levels, age-related differences were assessed using a t-test be-
tween young and middle-aged subjects. Treatment-induced changes
in middle-aged mice were ﬁrst compared using one-way ANOVA,
followed by a protected Dunnett's t-test comparing the vehicle treated
or ﬂuoxetine treated group to vortioxetine treated middle-aged mice.
Chi-square test was used to analyze categorical results (proportion of
animals that had intact memories in object placement test-OP or in
novel object recognition test-OR). Signiﬁcance is deﬁned as p b 0.05
for these analyses.
As most of the gene expression level results were not normally dis-
tributed, they were analyzed using non-parametric methods. Two-
sample Wilcoxon/Kruskal–Wallis test (non-parametric equivalent of 2
sample t-test) was used to compare age-induced changes in individual
genes. One-wayWilcoxon/Kruskal–Wallis test (non-parametric equiva-
lent of one-way ANOVA)was used to compare drug-induced changes in
individual genes followed by post-hoc Steel test (non-parametric equiv-
alent of the protected Dunnett's test) comparing vehicle or ﬂuoxetine
treated groups to vortioxetine treated middle-aged mice. Signiﬁcance
is deﬁned as p b 0.05.
3. Results
3.1. Middle-aged mice displayed deﬁcits in visuospatial memory but had
intact recognition memory, social preference, anxiety-like and depression-like
behavior compared to young mice
Behaviors of otherwise healthy 12 month old female mice were
compared to those of 3 month old mice in a battery of tests encom-
passing a variety of behavioral domains including cognitive (Fig. 1),
affective, emotional and social behaviors (Fig. 2).
Middle-agedmice performed signiﬁcantlyworse than youngmice in
the novel object placement test (OP), as assessed by preference score
(Fig. 1A, t(df = 29) =−3.71, p b 0.01) and by the proportion of animals
that had intact visuospatial memory (Fig. 1B: likelihood ratio χ2 =
12.91, p b 0.01). This visuospatial memory deﬁcit was not due to a
non-speciﬁc change in object exploration, as the exploration of the
objects during the training trial (Trial 1) did not differ between
middle-aged and young mice (young 18 ± 5.2 s, middle-aged: 18.3 ±
3.2 s). In contrast to the visuospatial memory deﬁcits observed in the
object placement test (OP), recognition memory was not signiﬁcantly
impaired in middle-aged mice tested in the novel object recognition
test (OR, Fig. 1C and D).
Consistent with the fact that the middle-aged mice in this study
were otherwise healthy, we did not ﬁnd robust deﬁcits in affective,
emotional or social behavior compared to youngmice, though some sig-
niﬁcant differences were evident (Fig. 2). In the open ﬁeld test (OF),
12 month old mice explored the center more than the 3 month old
mice (i.e., less anxiety-like behavior) (t(df = 29) = 3.05, p b 0.01,
Fig. 2A), though the difference in track length was not signiﬁcant
Fig. 1. Middle-aged mice display deﬁcits in visuospatial memory.Middle-aged (12 month old) mice display deﬁcits in visuospatial memory, assessed in the novel object placement
(a.k.a. novel object location), assessed as decreased preference for the displaced (novel) object (panel A) and also as a signiﬁcantly smaller proportion of 12 month old mice passing
the test with a preference score N55% (panel B). Recognition memory was not impaired in 12 month old mice, assessed in the novel object recognition test (panels C and D). n = 15–
16 per group. Means and standard errors are shown (panels A and C). * indicates signiﬁcant difference from young mice (p b 0.01).
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did not differ from3month oldmice in terms of immobility in the forced
swim test (FS), a measure for depression-like behavior (Fig. 2C), or
levels of social exploration in the social preference test (SP), a measure
for sociability (Fig. 2D).
3.2. Vortioxetine, but not ﬂuoxetine, improved visuospatial memory and
decreased depression-like behavior in middle-aged mice without affecting
general object exploration or locomotor activity
Chronic vortioxetine treatment signiﬁcantly improved cognitive
performance in middle-aged mice assessed as increased preference
score in the novel object placement test (OP). There was a main ef-
fect of treatment in preference scores (F(2,34) = 3.30, p b 0.05,
Fig. 3A) with vortioxetine-treated middle-aged mice performing
better than vehicle-treated middle-aged mice. Vortioxetine treat-
ment also signiﬁcantly improved the proportion of middle-aged
mice with intact visuospatial memory (likelihood ratio χ2 = 4.97,
p b 0.05, Fig. 3B) compared to vehicle treated middle-aged mice.
There was an apparent difference between vortioxetine and ﬂuoxe-
tine treated groups but this did not reach signiﬁcance in protected
post-hoc tests (p = 0.055 for preference scores, and p = 0.13 for
the proportion of animals with intact visuospatial memory). The ef-
fect of drug treatments on visuospatial memory was not due tonon-speciﬁc alterations of object exploration, as there was no signif-
icant change in total object exploration time during the training trial
(VEH 18.3 ± 3.2 s, VOR 9.0 ± 2.8 s, FLX 11.3 ± 3.5 s, F(2,28) = 2.31,
p = 0.11). Chronic drug treatment via food did not affect body
weight gains in middle-aged mice (before treatment: VEH 30.5 ±
1.0 g, VOR 28.5 ± 0.6 g, FLX 29.4 ± 0.8 g, after 1 month treatment:
VEH: 31.5 ± 1.1 g, VOR 31.7 ± 0.7 g, FLX 31.1 ± 1.0 g). Consistent
with previous results (Li et al., 2012, 2013), both drugs resulted in
a high level of SERT occupancy after 1 month of p.o. dosing in these
groups of middle-aged mice (VOR 84 ± 3%, FLX 97 ± 1%). In the
novel object recognition test (OR), there was no statistically signiﬁ-
cant change in recognition memory induced by any treatment
(Fig. 3C).
Depression-like behavior was assessed in the forced swim test (FS).
Vortioxetine, but not ﬂuoxetine, signiﬁcantly decreased immobility
in middle-aged mice. There was a signiﬁcant treatment effect
(F(2,54) = 3.87, p b 0.05, Fig. 3D and E), primarily due to vortioxetine
(p b 0.05, vortioxetine compared to vehicle). There was an apparent
difference between vortioxetine and ﬂuoxetine treatment but this
did not reach statistical signiﬁcance (p = 0.07). The vortioxetine-
induced reduction of immobility was not due to a global or non-
speciﬁc change in locomotor activity, as there was no signiﬁcant
change in total track length in the open ﬁeld test (OF): VEH 2467 ±
158 cm; VOR 2402 ± 96 cm; and FLX 2161 ± 100 cm. Neither
Fig. 2. Characterizationof young andmiddle-agedmice in affective, emotional and social domains. In the openﬁeld test, 12month oldmice had less anxiety-like behavior, assessed as
higher levels of center exploration (panel A) and did not differ in voluntary ambulation (track length, panel B) compared to 3 month old mice. There was no signiﬁcant alteration of
immobility in the forced swim test (panel C) or social exploration in the social preference test (panel D) in 12 month old mice. n = 15–19 per group for panels A–C, n = 10 per group
for panel D. Means and standard errors are shown. * indicates signiﬁcant difference from young mice (p b 0.05).
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havior in middle-aged mice assessed by center exploration (Fig. 3F) in
the open ﬁeld test (OF).
3.3. Middle-aged mice had wide-spread reduction in gene expression levels
compared to young mice, vortioxetine treatment increased expression of a
subset of these genes
The most robust age-related deﬁcit was detected in visuospatial
memory. As the hippocampus is critical in spatial memory (Mumby
et al., 2002), we focused our subsequent studies on this brain region.
The hippocampal gene expression levels were measured using quanti-
tative RT-PCR.
Compared to 3 month old mice, there was a widespread reduction in
gene expression in 12 month old mice (Table 1). These genes include
transcription and translation factors (Nfkb1, Fos, Creb1, and Fmr1),
genes related to signal transduction (Ntrk2, Camk2a, Jak2, Prkca, and
Gsk3b), neuroplasticity (Arc, Shank1, Nlgn2, Homer1, Dlg4, and Ncam1)
and neurotransmission (Scg3, Syp, Snap25, Vamp1, Htr1d, and Grin1).
Chronic vortioxetine treatment of middle-aged mice increased
expression of speciﬁc genes in several functional categories compared
to vehicle treated mice (Fig. 4), including: transcription and translation
factors (Nfkb1, Fos, and Fmr1), neuroplasticity (Arc, Shank1, and
Nlgn2), signal transduction (Camk2a) and neurotransmission (Rab3aand Dat). The effects of vortioxetine on the expression of some of
these genes were also signiﬁcantly different from that of ﬂuoxetine,
whichwas largely ineffective inmodifying gene expression. In addition,
almost all of these genes were reduced in 12month oldmice compared
to 3 month old mice. Therefore, changes in expression of these genes
were consistent with vortioxetine-induced improvements in the visuo-
spatial memory test. Please refer to Table S1 for common names, brief
descriptions of functions and statistical analysis for all genes measured
in this study.
3.4. Neither vortioxetine nor ﬂuoxetine altered hippocampal cell proliferation
in middle-aged mice
Middle-aged mice had reduced levels of hippocampal cell prolifera-
tion compared to young mice. There was a signiﬁcant reduction in the
number of cells in the subgranular zone of the dentate gyrus that incor-
porated the thymidine analog BrdU in 12 month old mice vs. 3 month
old mice (total number of BrdU positive cells in 10 dentate gyrus
subgranular zone regions in each animal: 3 month old 182 ± 9,
12 month old 36 ± 7, t(df = 14) =−12.5, p b 0.01). Chronic treatment
with vortioxetine did not signiﬁcantly change the number of BrdU
positive cells in the sub-granular zone of the dentate gyrus of middle-
agedmice (F(2,20)= 0.54, p=0.59, Fig. 5) compared to vehicle or ﬂuox-
etine treated mice. We found essentially the same pattern of results
Fig. 3. Behavioral effects of chronic antidepressant treatments in middle-aged mice. Vortioxetine (VOR) but not ﬂuoxetine (FLX) signiﬁcantly improved visuospatial memory in the
novel object placement test in middle-aged mice, assessed as preference score (panel A) or as the proportion of mice passing (panel B). There was no signiﬁcant treatment effect in the
novel object recognition test (panel C). In the forced swim test, vortioxetine, but not ﬂuoxetine, signiﬁcantly reduced depression-like behavior inmiddle-agedmice, assessed as increased
immobility (panel D, group summary and panel E, scatterplot). Neither vortioxetine nor ﬂuoxetine treatment altered anxiety-like behavior (center exploration in open ﬁeld, panel F). n=
7–19 per group.Means and standard errors are shown (panels A, C, D and F). * indicates signiﬁcant difference between vortioxetine and vehicle groups (p b 0.05) and+ indicates the com-
parison between vortioxetine and ﬂuoxetine (p value shown in graph) groups following overall signiﬁcant one-way ANOVA (p b 0.05). Dotted lines indicate the performance of young
mice for comparison only.
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granular zone regions of dentate gyrus: young 78 ± 23, middle-
aged + VEH 20 ± 7, middle-aged + VOR 21 ± 4, middle-aged + FLX
18 ± 5, n = 3–5 per group).
3.5. The effects of vortioxetine on visuospatial memorywere independent of
hippocampal levels of growth factors
Several growth factors were quantiﬁed in hippocampal homoge-
nates using commercial ELISA kits. In addition, TrkB (Ntrk2, the receptor
for BDNF and NT-3) was quantiﬁed by qPCR. There was no consistent
decrease or increase of growth factors in middle-aged mice compared
to young mice. Middle-aged mice had a higher level of NGF, lower
level of TrkB, and non-signiﬁcant changes in the levels of BDNF, IGF-1,
NT-3 and VEGF, compared to young mice (dotted line in Fig. 6, and
Table S2). There was also no age-related change in BDNF mRNA levels
measured by qPCR (data not shown). The effects of antidepressants on
growth factors levels were variable and patterns of change were not
consistent with the results of the object placement test (Fig. 6). Thus,
the observed changes in growth factors did not reﬂect the functional
differences observed in behavioral tests (impaired in aged mice and
altered by vortioxetine but not ﬂuoxetine treatment), nor did they
vary consistently by age. Please refer to Table S2 for detailed statistical
analysis results.
4. Discussion
Mild cognitive deﬁcits occur as early as middle-age and are predic-
tive of progressive deﬁcits in humans and in rodents (Larrabee and
Crook, 1994; Stone et al., 1997). Visuospatial ability shows a strong as-
sociation with age, in both humans and in rodent models (Aenlle
et al., 2009; Ennaceur et al., 2008; Hoogendam et al., 2014). This study
demonstrated an age-related cognitive deﬁcit in visuospatial memory
in healthymiddle-agedmice. Thiswas accompanied by global decreases
in gene expression related to diverse physiological functions and byextensive reduction in hippocampal cell proliferation, but not by a con-
sistent pattern of changes in growth factor levels. Chronic treatment
with the multimodal antidepressant, vortioxetine, but not ﬂuoxetine,
improved visuospatial memory and decreased depression-like behavior
in middle-aged mice, consistent with clinical ﬁndings that vortioxetine
improves both cognitive function and depression in old patients
(Katona et al., 2012). The improved cognitive function in middle-aged
mice treated with vortioxetine was accompanied by increased mRNA
levels of transcription factors,members of signal transduction pathways
and neuroplasticity markers. Most of these genes had lower transcript
levels in the hippocampus of middle-aged vs. young mice. In contrast,
neither hippocampal cell proliferation nor growth factor levels were
related to improved performance in the behavioral tasks.
The cognitive behavioral tests used in the study are not confounded
by stressors or aversive stimuli, do not require food orwater deprivation
(Ennaceur andMeliani, 1992; Gulinello et al., 2009) and can be repeated
in the same subjects. The object placement task is dependent on intact
hippocampal function and is analogous to the visuospatial memory
tests used in humans (Haladjian and Mathy, 2015; Raber, 2015),
which are likely associated with mental rotation ability (Kelly et al.,
2013; Vandenberg and Kuse, 1978). This type of cognitive test has
been used in assessing cognitive impairments in patients (Caterini
et al., 2002; Lawrence et al., 2000).
In otherwise healthymiddle-agedmice, age-associated impairments
in cognitive performance were evident in visuospatial memory but not
in object recognitionmemory, consistent with other reports (Ron-Harel
et al., 2008; Wimmer et al., 2012). However, some behavioral signs of
aging could still be detected. There was a modest reduction in total
track length in open ﬁeld. In the forced swim test, even though there
was no signiﬁcant overall increase of immobility in aged vs. young
mice, there appeared to be a subpopulation of middle-aged mice
displaying higher depression-like behavior (more than 60% of the
middle-aged mice displayed high levels of immobility compared to
less than 45% of young mice showing high levels of immobility). The
reduction in depression-like behavior seen after vortioxetine treatment
Fig. 4. Chronic vortioxetine, but notﬂuoxetine, increased plasticity-related gene expression inmiddle-agedmice.Data fromqPCRare expressed as relative expression levels to that of
vehicle-treated 12 month old mice. These genes include transcription and translation factors (panel A), synaptic plasticity markers (panel B), signal transduction (panel C) and proteins
involved in neurotransmission (panel D). VEH: vehicle; VOR: vortioxetine; FLX:ﬂuoxetine. Expression levels in 3month oldmice are indicatedwith a dotted line for comparison only. n=
10 per group. Means and standard errors are shown. * indicates signiﬁcant difference between vortioxetine and vehicle groups (p b 0.05), + indicates signiﬁcant (p b 0.05) difference
between vortioxetine and ﬂuoxetine groups following a signiﬁcant (p b 0.05) Wilcoxon/Kruskal–Wallis test (non-parametric equivalent of one-way ANOVA). ^ indicates non-signiﬁcant
difference between vortioxetine and ﬂuoxetine (p values shown in graph).
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depression-like behavior. This is of particular importance as even mild
depressive symptoms negatively impact cognitive function in middle-
aged and old subjects (Brevik et al., 2013).
Modulations of speciﬁc subtypes of 5-HT receptors are thought to be
critically involved in cognitive functions (for a review, see Meneses,
2013). For example, the 5-HT3 receptor antagonist ondansetronimproved spatial memory in aged rats (Fontana et al., 1995; Pitsikas
et al., 1993) and increased c-Fos expression (Urzedo-Rodrigues et al.,
2014). In addition, 5-HT1A receptor (du Jardin et al., 2014; Haider
et al., 2012) and 5-HT7 receptor modulation (Roberts and Hedlund,
2012) affects hippocampal dependent cognitive functions in rodents.
Results from the current study support the hypothesis that direct recep-
tor activities may contribute to the effects of vortioxetine (du Jardin
Fig. 5. Neither vortioxetine norﬂuoxetine reversed the age-related reduction in hippocampal stem cell proliferation. Panels A–D: representativemicroscopic images of dentate gyrus
stained for BrdU. Panel A: young mice. Panel B: middle-aged mice treated with vehicle (VEH). Panel C: middle-aged mice treated with vortioxetine (VOR). Panel D: middle-aged mice
treated with ﬂuoxetine (FLX). Scale bar: 400 μm. Panel E: total numbers of BrdU-positive cells from 10 dentate gyrus regions. Sample size = 7–8 per group. Means and standard errors
are shown. * indicates young mice signiﬁcantly different from vehicle-treated middle-aged mice in pair-wise t-test (p b 0.01).
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mice. First, vortioxetine improved visuospatial memory while ﬂuoxe-
tine was not effective. Second, whereas vortioxetine selectively in-
creased transcription of multiple genes in the hippocampus, ﬂuoxetine
had no effect on the majority of genes assessed. Furthermore, vorti-
oxetine signiﬁcantly decreased depression-like behavior in 12 month
old mice while ﬂuoxetine did not, which is consistent with the clinical
observation that elderly patients have a lower response to SSRIs
(Tedeschini et al., 2011) and that cognitive deﬁcits in depressed and/
or elderly patients are also relatively insensitive to SSRI treatment
(Herzallah et al., 2013). Therefore, our results support that vortioxetine
is working via a different mechanism than the SSRI ﬂuoxetine in this
model of age-related cognitive deﬁcits.
Altering gene expression and the consequent changes in protein
levels may be one mechanism of the improved cognitive function in
middle-aged mice after chronic antidepressant administration. First, as
synaptic plasticity is an active process, it is plausible that manipulating
this process will affect cognitive function, including visuospatial memo-
ry. Second, results from this study showed that changes in geneFig. 6. Hippocampal growth factors and growth factor receptor levels after antidepressant
per group) and standardized to the protein concentration of the tissue homogenate (pg/mg pro
and expressed as relative expression level using vehicle-treated middle-aged mice as 100. Dott
ferences inNT-3 level reached overall signiﬁcance in one-wayANOVA (pb 0.05). * indicates sign
comparison between vortioxetine and ﬂuoxetine (p value shown in graph). VEH: vehicle; VORexpression were consistent with the observed behavioral changes.
In middle-aged mice, the profound reduction in gene expression in
the hippocampus was accompanied with visuospatial memory im-
pairment in untreated and ﬂuoxetine treated animals. Increased hip-
pocampal transcription of a subset of these genes (including Nfkb1, Fos,
Fmr1, Camk2a, Arc, Shank1, Nlgn2, Rab3a, and Ndor1) was accompa-
nied with improvement of performance in this hippocampal-
dependent task in animals treated with vortioxetine. Third, the prod-
ucts of those genes affected by vortioxetine can be considered as related
to neuroplasticity, which plays a key role in learning and memory
(Mayford et al., 2012). For instance, Arc is an immediate early gene
critical to neuroplasticity, learning and memory (for a review, see
Korb and Finkbeiner, 2011). Its post-synaptic expression is induced by
exposure to novelty and the resultant increase in synaptic activity, the
dysfunction of which has been indicated as a fundamental mechanism
of memory impairment. Another example is Fmr1. The protein coded
by Fmr1 (the Fragile X mental retardation protein, FMRP) regulates
translation of a variety ofmRNAs (Sethna et al., 2014). Impaired expres-
sion of Fmr1 has been related to cognitive dysfunction in patients withtreatment inmiddle-agedmice. Growth factor levels were quantiﬁed by ELISA (n= 4–9
tein). The growth factor receptor TrkB (Ntrk2)was quantiﬁed by qPCR (n= 10 per group)
ed line denotes the levels in young mice. Means and standard errors are shown. Only dif-
iﬁcant difference between the vortioxetine andvehicle groups (p b 0.05) and ^ indicates the
: vortioxetine; FLX: ﬂuoxetine.
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gest that altered expression of Fmr1 may also play a role in cognitive
deﬁcits in middle-aged subjects as well as in developmental disorders.
Therefore, results from the current study support the hypothesis that
long-term changes in gene expression may contribute to the age-
related decline in cognition. We hypothesize that up-regulation of the
transcription factors that are reduced in middle-aged animals may be
a necessary prerequisite for the adequate expression of the speciﬁc
genes needed for maintaining synaptic plasticity and cognitive
functions.
Neurogenesis which has been shown to be involved in cognitive
impairment and depression in humans and in a variety of rodent
models, is a function of serotonergic regulation and may affect the re-
sponse to antidepressants in both cognitive and affective behavioral do-
mains (Adeosun et al., 2014; Alenina and Klempin, 2015; Anacker,
2014; Biscaro et al., 2012; Braun and Jessberger, 2014; Chadwick et al.,
2011; Cho et al., 2015; Dimitrov et al., 2014; Gundersen et al., 2013;
Hill et al., 2015; Jiang et al., 2015; Lin and Wang, 2014; Mendez-David
et al., 2013; Morais et al., 2014; O'Leary and Cryan, 2014; Parihar et al.,
2013; Pereira Dias et al., 2014; Ransome et al., 2012; Rotheneichner
et al., 2014; Schoenfeld and Cameron, 2015; Seib et al., 2013; Seraﬁni
et al., 2014; Shetty, 2014; Suarez-Pereira et al., 2015; Yau et al., 2014).
In young adult mice, antidepressants increase stem cell proliferation
(Hodes et al., 2010; Santarelli et al., 2003; Tanti et al., 2013). However,
in the current study, amelioration of the deﬁcits in the hippocampal-
dependent object placement task (OP) was not related to levels of
stem cell proliferation, nor was there evidence of increased levels of ap-
optosismarkers or gliosis (Gfap, Table S1), consistentwith the relatively
speciﬁc behavioral deﬁcits and otherwise normal behavior of healthy
middle-aged mice. These data are also consistent with previous studies
dissociating performance in hippocampal tasks from levels of stem cell
proliferation in agedmice (Walter et al., 2011). The lack of treatment ef-
fect on hippocampal stem cell proliferation in the middle-aged animals
is also consistent with previous reports indicating that ﬂuoxetine does
not increase stem cell proliferation in older (N8 months) rodents
(Couillard-Despres et al., 2009; Cowen et al., 2008; Guirado et al.,
2012). While the reasons that antidepressants do not increase stem
cell proliferation in middle-aged subjects are unclear, it appears that al-
ternative mechanisms (i.e., increased neuroplasticity and gene expres-
sion) are sufﬁcient to improve the cognitive functions in middle-aged
mice.
The relationship between hippocampal growth factor levels and
cognitive function seems to be complex and insufﬁcient to explain ei-
ther the existence or the reversal of cognitive impairment. Growth fac-
tor levels have a variable relationship with aging, with either increased,
decreased or unchanged levels reported compared to young animals
(Croll et al., 1998; Hattiangady et al., 2005; Katoh-Semba et al., 1998;
Muller et al., 2012; Shetty et al., 2005; Silhol et al., 2005, 2007). In
young adult rodents, the effects of ﬂuoxetine on growth factors in hip-
pocampus are just as variable (Altar et al., 2003; Coppell et al., 2003;
Dias et al., 2003; Nibuya et al., 1996). Furthermore, although we found
some changes in growth factor levels after chronic antidepressant
treatment in middle-aged mice, none of these are consistent with the
observed changes in visuospatial memory. It has been reported else-
where that improvement in spatial memory in aged rodents were not
accompanied by a change in growth factor levels (Kumar et al., 2012).
It is important to note that this does not preclude an important role
for drug-induced changes in hippocampal growth factors in other
behavioral domains not addressed here. Regulation of growth factor
levels in other brain regions could also have important functional
consequences.
5. Conclusions
In conclusion, aging in healthy middle-aged mice is associated with
speciﬁc,mild deﬁcits in cognitive function concomitantwithwidespreadreduction of gene expression, including reduced expression of several
transcription factors that may herald the inability to respond to stimuli
with critical regulation of downstreamprotein synthesis. Cognitive func-
tion in middle-aged mice was improved by the multimodal antidepres-
sant vortioxetine. The results from current study support the
hypothesis that the underlyingmechanisms bywhich vortioxetine affect
cognition involve increased expression of genes related to
neuroplasticity.
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